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The crystal and molecular structure of 6-bromo-2-(furan-2-yl)-3-(prop-2-ynyl)-3H-imidazo[4,5-b]pyridine (C
13
H
8
BrN
3
O) has
been investigated from single crystal X-ray diffraction data. The primary focus is to investigate the molecular geometry of this
compound in the solid state along with the associated intermolecular hydrogen bonding and related 𝜋-𝜋 interactions present in
the crystal packing. This compound crystallizes in the monoclinic space group 𝑃2
1
/𝑛 with cell parameters: 𝑎 = 4.39655(19) A˚,
𝑏 = 13.5720(5) A˚, 𝑐 = 20.0471(5) A˚, 𝛽 = 94.753(3), 𝑉 = 1192.10(7) A˚3, 𝐷 = 1.683 g⋅cm−3, and Z = 4. The crystal structure is
stabilized by 𝜋-𝜋 interactions and intermolecular C–H⋅ ⋅ ⋅N and C–H⋅ ⋅ ⋅O interactions.
1. Introduction
The imidazo[4,5-b]pyridine moiety is an important hetero-
cyclic nucleus having been used extensively in medicinal
chemistry. In fact, different compounds derived from this
structure have been tested for their potential as anticancer [1],
tuberculostatic [2], antimitotic [3], and antineuroinflamma-
tory activities [4].
Due to their great importance, many synthetic strategies
have been developed to obtain a variety of substituted struc-
tures of this class. The most popular synthetic approach gen-
erally involves the cyclocondensation of 2,3-pyridinediamine
with carboxylic acid derivatives or with aldehydes [5, 6].
Recently, an ecofriendly synthetic approach including an
oxidation in aqueous medium has been claimed [7].
In a previous study, we reacted 6-bromo-2-(furan-2-
yl)-3H-imidazo[4,5-b]pyridine with benzyl chloride in the
presence of a catalytic quantity of tetra-n-butylammonium
bromide, under mild conditions, to form 3-benzyl-6-bromo-
2-(furan-2-yl)-3H-imidazo[4,5-b]pyridine [8]. In this work,
we have synthesized the 3-prop-2-ynyl analogue which
is 6-bromo-2-(furan-2-yl)-3-(prop-2-ynyl)-3H-imidazo[4,5-
b]pyridine (1) (Scheme 1). Owing to the potential biological
activities of imidazo[4,5-b]pyridine derivatives, a clear need
exists for the preparation of new compounds. In this regard,
compound 1 presents some interesting features in the search
for new biologically active substances as it contains an
additional heterocyclic ring and an alkyne group for easy
modification.
2. Material and Methods
6-Bromo-2-furyl-3H-imidazo[4,5-b]pyridine (0.30 g, 1.13
mmoL) was dissolved in DMF (15mL) and potassium
carbonate (0.2 g, 1.48mmol), and tetra-n-butylammonium
bromide (0.04 g, 0.1mmol) and propargyl bromide (0.12mL,
1.36mmoL) were then added. Stirring was continued at
room temperature for 12 h. The mixture was filtered, and the
solvent was removed under reduced pressure. The residue
was chromatographed on a column of silica gel with ethyl
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Scheme 1: Compound 1.
acetate-hexane (1/2) as eluent. Compound 1 was obtained as
yellow solid.
Single crystals of 1, C
13
H
8
BrN
3
O, were crystallized from
ethanolic solution. A suitable crystal was selected and mea-
sured on an Agilent SuperNova Atlas Dual Source, Agilent
Technologies diffractometer using the CrysAlisPro software.
The crystal was kept at 199.95(10) K during data collection.
Using Olex2 [9], the structure was solved with the SHELXS
[10] structure solution program using direct methods and
refined with the SHELXL [10] refinement package using least
squares minimisation. Nonhydrogen atoms are refined with
anisotropic displacement parameters.Themolecular connec-
tivity and the crystal packing diagram were drawn using the
Mercury (CCDC) program [11] and PyMol [12]. Geometrical
calculations were done using Mercury (CCDC) program.
3. Results and Discussion
The details of the crystal data, data collection, and structure
refinements are shown in Table 1 and the unique molecule in
the crystal structure of 1 in Figure 1.
This compound crystallizes in the monoclinic space
group 𝑃2
1
/𝑛 with four molecules in the unit cell. The core
heterocyclic structure of themolecule is approximately planar
with deviations lower than 0.064 A˚ from themean plane.The
molecular geometry is stabilized by intermolecular C–H⋅ ⋅ ⋅N
andC–H⋅ ⋅ ⋅O interactions which contribute to the stability of
the crystal packing (Figure 2). Those interactions involve the
relatively acidic hydrogen atom of the terminal alkyne.
An analysis of the crystal packing shows the presence
of intermolecular 𝜋-𝜋 interactions between the imidazole
ring and the pyridine ring of two contiguous molecules.
This interaction has a 3.635 A˚ centroid-centroid distance (see
Figure 3).
These 𝜋-𝜋 interactions generate arrays of parallel
aromatic subunits along the crystallographic 𝑎-direction
(Figure 4), while C–H⋅ ⋅ ⋅N and C–H⋅ ⋅ ⋅O interactions form
a zigzag structure along the 𝑏 direction (Figure 5).
A general view of the crystal packing of compound 1 is
summarized in Figure 6, where all intermolecular interac-
tions are shown.The arrays formed by 𝜋-𝜋 interactions along
the crystallographic 𝑎-direction are shown in green colour.
Besides, intermolecular C–H⋅ ⋅ ⋅N and C–H⋅ ⋅ ⋅O interactions
are represented with yellow dotted lines providing the gener-
ation of a zigzag structure (blue colour) along the 𝑏 direction.
Table 1: Crystal data and structure refinement for compound 1.
Empirical formula C13H8BrN3O
Formula weight 302.13
Temperature/K 199.95 (10)
Crystal system Monoclinic
Space group 𝑃2
1
/𝑛
a/A˚ 4.39655 (19)
b/A˚ 13.5720 (5)
c/A˚ 20.0471 (5)
𝛽/∘ 94.753 (3)
Volume/A˚3 1192.10 (7)
Z 4
𝐷calc mg/mm
3 1.683
m/mm−1 4.629
F (000) 600.0
Crystal size/mm3 0.141 × 0.125 × 0.088
2Θ range for data collection 7.88 to 145.74∘
Index ranges −5 ≤ h ≤ 4, −16 ≤ k ≤ 16, −24 ≤ l ≤ 24
Reflections collected 11229
Independent reflections 2362 [R(int) = 0.0455]
Data/restraints/parameters 2362/0/163
Goodness-of-fit on 𝐹2 1.201
Final R indexes [𝐼 ≥ 2𝜎(𝐼)] 𝑅
1
= 0.0389, w𝑅
2
= 0.1052
Final R indexes [all data] 𝑅
1
= 0.0488, w𝑅
2
= 0.1092
Largest diff. peak/hole/e A˚−3 0.47/−0.38
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Figure 1: Projection view of 1.
Tables 2 and 3 summarize the crystallographic data with
all bond lengths and bond angles for compound 1.
4. Conclusions
The compound 6-bromo-2-(furan-2-yl)-3-(prop-2-ynyl)-
3H-imidazo[4,5-b]pyridine has been synthesized as a
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Figure 2: Intermolecular C–H⋅ ⋅ ⋅N and C–H⋅ ⋅ ⋅O interactions for compound 1.
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Figure 3: Intermolecular 𝜋-𝜋 interactions.
Figure 4: Arrays of parallel aromatic subunits formed by intermolecular 𝜋-𝜋 interactions.
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Figure 5: Intermolecular C–H⋅ ⋅ ⋅N and C–H⋅ ⋅ ⋅O interactions forming a zigzag structure along the 𝑏 direction.
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Figure 6: Arrays formed by 𝜋-𝜋 interactions (green colour) along the crystallographic 𝑎-direction, and intermolecular C–H⋅ ⋅ ⋅N and C–
H⋅ ⋅ ⋅O interactions (showed with yellow dotted lines) forming a zigzag structure (blue colour) along the 𝑏 direction.
Table 2: Bond lengths for compound 1.
Atom Atom Length/A˚
Br1 C2 1.894 (3)
C1 C2 1.391 (5)
C1 N1 1.337 (5)
C2 C3 1.386 (5)
C3 C4 1.395 (5)
C4 C5 1.403 (4)
C4 N3 1.379 (4)
C5 N1 1.332 (4)
C5 N2 1.380 (4)
C6 C7 1.445 (5)
C6 N2 1.387 (4)
C6 N3 1.319 (4)
C7 C8 1.340 (5)
C7 O1 1.366 (4)
C8 C9 1.447 (6)
C9 C10 1.307 (6)
C10 O1 1.353 (5)
C11 C12 1.465 (5)
C11 N2 1.462 (4)
C12 C13 1.178 (5)
new starting material for the development of products
with biomedical activities. Its crystal structure has been
determined with good precision and accuracy.Themolecular
structure and crystal packing are stabilized by intermolecular
C–H⋅ ⋅ ⋅N and C–H⋅ ⋅ ⋅O hydrogen bonds and intermolecular
𝜋-𝜋 interactions with the generation of an infinite network.
Table 3: Bond angles for compound 1.
Atom Atom Atom Angle/∘
N1 C1 C2 123.4 (3)
C1 C2 Br1 118.1 (3)
C3 C2 Br1 119.5 (3)
C3 C2 C1 122.3 (3)
C2 C3 C4 115.3 (3)
C3 C4 C5 117.7 (3)
N3 C4 C3 132.0 (3)
N3 C4 C5 110.3 (3)
N1 C5 C4 127.6 (3)
N1 C5 N2 126.6 (3)
N2 C5 C4 105.8 (3)
N2 C6 C7 123.7 (3)
N3 C6 C7 123.2 (3)
N3 C6 N2 113.1 (3)
C8 C7 C6 135.6 (3)
C8 C7 O1 110.6 (3)
O1 C7 C6 113.8 (3)
C7 C8 C9 104.7 (4)
C10 C9 C8 107.3 (4)
C9 C10 O1 110.9 (4)
N2 C11 C12 111.9 (3)
C13 C12 C11 176.4 (4)
C5 N1 C1 113.7 (3)
C5 N2 C6 105.8 (3)
C5 N2 C11 124.4 (3)
C6 N2 C11 129.7 (3)
C6 N3 C4 105.0 (3)
C10 O1 C7 106.4 (3)
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